VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS and Selten Pharma Announce Agreement for the Development and Commercialization Rights to Treatments for Pulmonary Arterial Hypertension (PAH)
CAMPBELL, CA , and SAN CARLOS, CA -- (Marketwired) -- 01/09/17 -- VIVUS, Inc. ( NASDAQ : VVUS) and Selten Pharma, Inc. , announced VIVUS' acquisition from Selten of exclusive, worldwide rights for the development and commercialization of tacrolimus and ascomycin for the treatment of Pulmonary
View HTML